Pharma & Healthcare – the latest on Takeda Pharmaceutical improper drug ads, FDA spying and more.
FDA spying may have broken whistleblower laws, congressional probe finds by Arlene Weintraub Published on FiercePharma
Two years after press reports revealed that the FDA was extensively monitoring communications by some of its employees, a congressional committee has wrapped up its investigation. The verdict, announced by Rep. Daryl Issa (R-CA) and Sen. Charles Grassley (R-IA): The agency overstepped its authority–and may have broken laws meant to protect whistleblowers… [ Read More ]
Takeda Pharmaceutical Admits To Improper Drug Ads by Kana Inagaki Published on WSJ
The chief executive of Japan’s largest pharmaceutical company admitted the company had used “inappropriate expressions” in promoting its drug used to treat high blood pressure, but denied the drug maker had tampered with research data… [ Read More ]
Regulatory burdens on biosimilar meds will cost patients in Ill by Guest Published on The State Journal
Great advances are being made treating patients with serious illnesses using drugs known as biologics.Produced using biological material rather than chemicals, biologic medications work in concert with the body’s natural defenses and often are more effective than traditional drugs… [ Read More ]Live Industry News
Follow @ACI_Pharma and @ACI_Health
Join ACI Pharmaceuticals/Biotech/Life Sciences Experts Group
Join ACI Healthcare: Legal, Regulatory, and Compliance Experts Group
Related Events
For the complete list of all Pharmaceutical related upcoming events: Click Here
For the complete list of all Healthcare related upcoming events: Click Here
To download past Pharmaceutical conference materials: Click Here
To download past Healthcare conference materials: Click Here